Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Abbott Pulls Absorb Stent Off The Market, Citing Low Sales

Executive Summary

Abbott is giving up on selling its first-generation biosorbable coronary stent, which failed to match the performance of contemporary metallic drug-eluting stents in clinical trials. The company says it will continue working on the next-generation biosorbable stents and continue the ongoing trials of Absorb GT1 BVS.


Related Content

Medtech's High-Earners: 2016 Executive Payouts Boosted By Bonuses, Stock Awards
Global Approvals Analysis: Diabetes, Drug-Eluting Stents Lead List Of Non-US Approvals in October
US Approvals Analysis: Abbott Leads Another Strong Month For Novel Approvals
Earnings Winners & Losers: The Large Diversified Firms, ABT, BAX, CAH, JNJ
EuroPCR 2017: TAVR Continues To Beat Surgery; Bioabsorbable Stents Not Going Away
Starts & Stops: ICS' Emblok Medtronic's Arctic Front, Abbott's Absorb, Boston Scientific's S-ICD
Abbott To Restrict Absorb To Registries In Europe For At Least A Year


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts